• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND IN.PACT ADMIRAL PACLITAXEL-ELUTING PTA BALLOON CATHETER; DRUG-ELUTING PERIPHERAL TRANSLUMINAL ANGIOPLAS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND IN.PACT ADMIRAL PACLITAXEL-ELUTING PTA BALLOON CATHETER; DRUG-ELUTING PERIPHERAL TRANSLUMINAL ANGIOPLAS Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Stroke/CVA (1770); Hemorrhage/Bleeding (1888); Myocardial Infarction (1969); Renal Failure (2041); Rupture (2208); Obstruction/Occlusion (2422); Embolism/Embolus (4438)
Event Date 08/10/2023
Event Type  Injury  
Manufacturer Narrative
A2: average age a3: majority sex literature ref: doi.Org/10.1186/s42155-023-00390.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Medtronic received a literature article title 'application of first-generation high and low-dose drug-coated balloons to the femorop opliteal artery disease: a sub-analysis of the popcorn registry'.The study used a clinical database of the prospective multicenter registry of drug-coated balloon for femoropopliteal disease (popcorn).Popcorn is an ongoing prospective multicenter observational study that registered adult patients (aged=20 years) undergoing dcb treatment for femoropopliteal lesions of symptomatic peripheral artery disease (rutherford categories 2¿5) [8] at 81 cardiovascular centers across japan.Among 2507 patients undergoing fpa evtwith dcb for symptomatic lead, 602 patients were treated with lowdose non-medtronic dcb, and the remaining 1905 patients were treated with in.Pact admiral high-dose dcb.There were no differences in patient/lesion characteristics, procedural success rates, or complications between the two groups.Perioperative outcomes for the in.Pact admiral high-dose dcb included normal blood flow after dcb (95.8%), dissection grade d or severer (4.1%), bailout stenting (3.1%), perioperative complication(s) (4.8%), target lesion revascularization (evt) (0.9%), target lesion revascularization (bypass) (0.1%), distal embolism (1.0%), transfusion for bleeding (0.5%), acute occlusion (0.1%), vessel rupture (0.1%), blue toe syndrome (0.1%), major amputation (0.4%), myocardial infarction (0.1%), stroke (0.1%) and renal impairment (0.3%).The high dose dcb group had 86.2% freedom from restenosis and 92.5% freedom from reintervention.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IN.PACT ADMIRAL PACLITAXEL-ELUTING PTA BALLOON CATHETER
Type of Device
DRUG-ELUTING PERIPHERAL TRANSLUMINAL ANGIOPLAS
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
EI 
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
EI  
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key17927177
MDR Text Key325569468
Report Number9612164-2023-04632
Device Sequence Number1
Product Code ONU
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P140010
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature
Reporter Occupation Other
Type of Report Initial
Report Date 10/12/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 09/15/2023
Initial Date FDA Received10/12/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age75 YR
Patient SexMale
-
-